No abstract available.
Haloperidol* ; Humans*

No abstract available.
Carbamazepine* ; Haloperidol*

No abstract available.
Haloperidol* ; Homovanillic Acid* ; Plasma*

No abstract available.
Animals ; Haloperidol* ; Mice*

No abstract available.
Benztropine* ; Haloperidol* ; Saliva*

No abstract available.
Haloperidol* ; Homovanillic Acid* ; Humans ; Plasma*

OBJECTIVES: This study was aimed at investigating the effect of haloperidol on alcohol craving in patients wih alcohol dependence. METHODS: Eighteen patients with alcohol dependence were divided randomly into two groups of nine patients each: one haloperidol group and the other, placebo group. The medication for each group was done for 14 days. Alcohol craving and difficulty in resisting drinking were measured on day 1 and day 14, each consisting of a series of four assessments. Assessment 0 was basal levels. Assessment 1 was made 3 hours after medication. Assessment 2 was made after alcohol intake in a dose of 0.4gm of 100% alcohol/kg body weight and assessment 3 was done after the second alcohol intake in the same amount. RESULTS: The results were as follows: 1) With acute treatment, placebo group showed a significant increase in alcohol craving whereas haloperidol group did not show any change after the first and second alcohol intake. 2) With chronic treatment, both groups showed significant increase in the alcohol craving after alcohol intake. 3) Haloperidol did not increase difficulty in resisting drinking after acute treatment, however, with chronic treatment, it resulted in a significant increase of the difficulty in resisting drinking. CONCLUSIONS: From these results, the authors suggest that an acute treatment of haloperidol lowers alcohol craving in patients with alcohol dependence, but the effect does not maintain itself with chronic treatment.
Alcoholism* ; Body Weight ; Drinking ; Haloperidol* ; Humans

There have been many reports stating that halperidol premedication has been used for sefative and antiemetic effects. Therefore we utilized haloperidol as a premedicant for the purpose of obtaining the above effects. Over a period of one year from march 1978 to February 1979, 0.1mg haloperidol per kilogram of body weight was given to 747 patients. The results were as follows. 1)The extrapyramidal symptioms appeared in children, especially in the 10-year old group. 2) Large doses of haloperidol were more likely to cause to extrapyramidal symptoms than smaller doses(over 0.1mg/kg) 3)The effects of haloperidol lasted for a considerable duration of time after administration, (about 24-48 hous).
Antiemetics ; Body Weight ; Child ; Haloperidol* ; Humans ; Premedication*

OBJECTIVE: To evaluate the clinical efficacy of adjuvant sertraline treatment in chronic schizophrenic patients, we carried out a double-blind, placebo controlled study. METHOD: Thirty six inpatients who fulfilled DSM-III-R criteria for chronic schizophrenia were randomly assigned to sertraline and placebo groups in a double-blinded fashion. A history of at least 2 years of illness and at least six months of hospitalization were prerequisities for inclusion in the study. Patients were received sertraline 50mg or placebo for 8 weeks in addition to their routine haloperidol regimen, Positive and Negative Syndrome Scale(PANSS), Clinical Global Impression(CGI), Simpson-Angus Scale(S-A) were evaluated at 5 points ; baseline, 2, 4, 6 and 8 weeks of treatment. RESULTS: The groups were controlled for age, gender, and length of illness. There were no significant differences in three PANSS factros(positive, negative, general), CGI and S-A scale scores at any between sertraline and placebo treatment. CONCLUSION: This placebo controlled study showed no significant effects of sertraline on negative and positive symptoms in chronic schizophrenic patients.
Haloperidol ; Hospitalization ; Humans ; Inpatients ; Schizophrenia* ; Sertraline*

OBJECTIVES: The authors have intended to know the drug interaction of fluoxetine and haloperidol when coadministering two drugs to the chronic schizophrenics by assessing the changes of positive, negative symptoms and extrapyramidal symptoms. METHOD: We selected 38 patients, the chronic schizophrenics with no physical problems. they are randomly assigned to placebo group and drug group. And then, placebo or fluoxetine 20mg were administered to the subjects of each group during 8 week period. We have assessed their psychopathology and extrapyramidal symptoms using positive and Negative Syndrome Scale(PANSS), Clinical Global Impression(CGI), Simpson-Angus Scale at o, 2, 4, 6, 8 week during the period. RESULTS: 38 patients have completed the study during 8 week. 1) PANSS, CGI : no significant difference between groups and no significant change according to the times. 2) Simpson-Angus Scale : no significant changes. CONCLUSION: When co-administering fluoxetine and haloperidol, there were no significant changes of psychopathology and extrapyramidal symptoms. There results suggest that it is safe to coadminister fluoxetine to schizophrenic with haloperidol treatment.
Drug Interactions ; Fluoxetine* ; Haloperidol* ; Humans ; Psychopathology*